Literature DB >> 25388084

Hypereosinophilic syndrome as a cause of fatal thrombosis: two case reports with histological study.

Kumi Fujita1, Hiroyasu Ishimaru, Kazuhiro Hatta, Yoichiro Kobashi.   

Abstract

Herein we present two cases of hypereosinophilic syndrome with a unique clinical presentation. One patient showed severe systemic thrombosis with splenic rupture and the other patient showed finger gangrene with various systemic symptoms. Both patients were examined histologically, and several characteristics were noted. First, fresh or organized thrombosis with marked eosinophilic infiltration was observed in the cavity and walls of the thrombosed vessels. Second, many eosinophils showed degranulation and were positive for eosinophilic cationic protein on immunohistological examination. Third, the structures of thrombosed vessels were well preserved, which is not observed in systemic vasculitis. These patients exhibited no neoplastic features and were treated with prednisolone with excellent therapeutic results.

Entities:  

Mesh:

Year:  2015        PMID: 25388084     DOI: 10.1007/s11239-014-1151-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  13 in total

1.  The hypereosinophilic syndromes.

Authors:  W R Hardy; R E Anderson
Journal:  Ann Intern Med       Date:  1968-06       Impact factor: 25.391

Review 2.  The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Authors:  M J Chusid; D C Dale; B C West; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

Review 3.  The idiopathic hypereosinophilic syndrome.

Authors:  P F Weller; G J Bubley
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

4.  Enhancement of factor XII dependent reactions by eosinophil cationic protein.

Authors:  P Venge; R Dahl; R Hällgren
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

5.  Enhancement of urokinase-induced plasminogen activation by the cationic protein of human eosinophil granulocytes.

Authors:  R Dahl; P Venge
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

6.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

7.  Treatment of hypereosinophilic syndrome with imatinib mesilate.

Authors:  Gerald J Gleich; Kristin M Leiferman; Animesh Pardanani; Ayalew Tefferi; Joseph H Butterfield
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Hypereosinophilia with systemic thrombophlebitis.

Authors:  Hiroyuki Kanno; Naohisa Ouchi; Masatoshi Sato; Tsukasa Wada; Takashi Sawai
Journal:  Hum Pathol       Date:  2005-05       Impact factor: 3.466

9.  Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Authors:  Jelena V Jovanovic; Joannah Score; Katherine Waghorn; Daniela Cilloni; Enrico Gottardi; Georgia Metzgeroth; Philipp Erben; Helena Popp; Christoph Walz; Andreas Hochhaus; Catherine Roche-Lestienne; Claude Preudhomme; Ellen Solomon; Jane Apperley; Michela Rondoni; Emanuela Ottaviani; Giovanni Martinelli; Finella Brito-Babapulle; Giuseppe Saglio; Rüdiger Hehlmann; Nicholas C P Cross; Andreas Reiter; David Grimwade
Journal:  Blood       Date:  2007-02-13       Impact factor: 22.113

Review 10.  Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality.

Authors:  J W Oliver; I Deol; D L Morgan; V S Tonk
Journal:  Cancer Genet Cytogenet       Date:  1998-12
View more
  6 in total

Review 1.  Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review.

Authors:  Su-Jun Gao; Wei Wei; Jiang-Tao Chen; Ye-Hui Tan; Cheng-Bao Yu; Mark Robert Litzow; Qiu-Ju Liu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

2.  Polyarteritis Nodosa with Marked Eosinophilia, Associated with Severe Gastrointestinal Tract Involvement and Recurrent Venous Thrombosis.

Authors:  Hiroshi Oiwa; Kohei Taniguchi; Natsuki Miyoshi; Keiko Sasaki; Kouichi Ichimura; Tetsushi Kubota; Daisuke Sato
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

3.  Idiopathic hypereosinophilic syndrome with cutaneous necrosis and multiorgan embolism.

Authors:  Huan Wang; Hua Zhong; WenChieh Chen; Haixing Cheng; Fei Hao; Zhiqiang Song
Journal:  JAAD Case Rep       Date:  2019-11-18

4.  The Neutrophil/Lymphocyte Ratio is an Independent Predictor of All-Cause Mortality in Patients with Idiopathic Hypereosinophilic Syndrome.

Authors:  Junshuai Xue; Jianjun Jiang; Yang Liu
Journal:  J Inflamm Res       Date:  2022-03-15

5.  Eosinophil-to-Monocyte Ratio as a Candidate for a Novel Prognostic Marker in Acute Pulmonary Embolism: Is it a Consumptive Mechanism?

Authors:  Şeyhmus Külahçıoğlu; Hacer Ceren Tokgöz; Özgür Yaşar Akbal; Berhan Keskin; Barkın Kültürsay; Seda Tanyeri; Doğancan Çeneli; Kadir Bıyıklı; Ali Karagöz; Süleyman Çağan Efe; İbrahim Halil Tanboğa; Nihal Özdemir; Cihangir Kaymaz
Journal:  Anatol J Cardiol       Date:  2022-09       Impact factor: 1.475

6.  Thrombosis in the portal venous system caused by hypereosinophilic syndrome: A case report.

Authors:  Jinfeng Lin; Xiaoying Huang; Weihua Zhou; Suyan Zhang; Weiwei Sun; Yadong Wang; Ke Ren; Lijun Tian; Junxian Xu; Zhilong Cao; Zunguo Pu; Xudong Han
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.